Johnson was coming off a Pro Bowl season in 2023 and was expected to be a big piece of the Jets defense. His injury was a big ...

NEW YORK (Reuters) - The U.S. Department of Health & Human Services may seek over $1 billion from Johnson & Johnson as ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...

Holdout creditors who claim tainted baby powder gave them ovarian cancer urged a judge to reject Johnson & Johnson’s plan to ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

Johnson & Johnson (JNJ) faces a $1B+ reimbursement demand for cancer cases linked to talc products. Read more here.

Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share.

In its motion to dismiss, J&J asserted that the plaintiff did “not allege a concrete harm or injury-in-fact” — a claim with ...

Two attempts by Johnson & Johnson to resolve approximately 60,000 talcum powder lawsuits through bankruptcy courts have ...